- Ocular Therapeutix (OCUL, Financial) announces inducement awards for new hires, including Executive Director Thomas J. Cella.
- The awards include non-statutory stock options and restricted stock units with specific vesting schedules.
- The stock options have a $6.30 exercise price, aligning with Ocular's stock closing price on the grant date.
Ocular Therapeutix, Inc. (OCUL), a leading biopharmaceutical company, has announced the granting of inducement awards to two new employees, effective April 7, 2025. The awards are part of the company's 2019 Inducement Stock Incentive Plan and are compliant with Nasdaq Listing Rule 5635(c)(4). This initiative aims to encourage key executives and staff, fostering long-term commitment to the company's growth and success.
Thomas J. Cella, the newly appointed Executive Director of Payer Access, received inducement awards consisting of a non-statutory stock option to purchase up to 26,000 shares of Ocular common stock and a restricted stock unit (RSU) award for 8,500 shares. Similarly, another newly hired non-executive employee was granted a non-statutory stock option to purchase 23,500 shares and an RSU award for 7,700 shares.
Each stock option comes with an exercise price of $6.30, which is the closing price of Ocular's common stock on the Nasdaq Global Market on the grant date. The options are structured to vest over a four-year period, with 25% vesting on March 31, 2026, for Mr. Cella and March 10, 2026, for the other employee, followed by equal monthly installments over the subsequent three years. The RSUs will vest in equal annual installments over three years, starting April 7, 2026, subject to the continued service of the recipients.
Ocular Therapeutix is renowned for its commitment to improving retinal treatments and is actively involved in clinical trials and product development, leveraging its proprietary ELUTYX™ bioresorbable hydrogel technology across its innovative product pipeline.
